Wilson Sonsini Goodrich & Rosati and Cooley advised Kura Oncology. Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision...
Kura Oncology’s Collaboration with Kyowa Kirin
AVROBIO’s Merger with Tectonic Therapeutic
Leerink Partners is serving as exclusive financial advisor to Tectonic and Cooley LLP is serving as legal counsel to Tectonic. Leerink Partners and TD Cowen are...
SystImmune’s Licensing and Collaboration Agreement with Bristol Myers Squibb
Cooley advised SystImmune on the transaction. SystImmune announced its exclusive license and collaboration agreement with Bristol Myers Squibb (NYSE: BMY) for SystImmune’s BL-B01D1. Under the terms of...
Seven and Eight Biopharmaceuticals’ License Agreement with Eikon Therapeutics
Cooley advised Seven and Eight Biopharmaceuticals on the deal. Seven and Eight Biopharmaceuticals Inc. announced that it has signed an exclusive licensing agreement with Eikon Therapeutics....
Impact Therapeutics’ Global Partnership with Eikon Therapeutics
Cooley advised Impact Therapeutics on the deal. Impact Therapeutics and Eikon Therapeutics announced that the companies have entered into a global license and collaboration agreement for PARP1 selective inhibitors...
Roche’s Acquisition of Zion Pharma’s Lead Program Title
Cooley advised Zion Pharma Limited on the deal. Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, announced the acquisition of its...
RTW’s $125 Million Investment in Milestone Pharmaceuticals
Gibson Dunn acted as legal advisor to RTW, and Cooley acted as legal advisor to Milestone. Milestone Pharmaceuticals Inc. announced that it has entered into a...
Kite’s Acquisition of Tmunity
Cooley advised Tmunity on the deal. Tmunity, a clinical-stage biotechnology company, announced its agreement to sell to Kite, a global biopharmaceutical company. The acquisition will provide...